Literature DB >> 8609895

Coupling of I1-imidazoline receptors to diacylglyceride accumulation in PC12 rat pheochromocytoma cells.

D Separovic1, M Kester, P Ernsberger.   

Abstract

The I1-subtype of imidazoline binding sites has been characterized concerning binding specificity and tissue localization, and several physiological functions have been ascribed to it. However, the signaling pathways coupled to this putative receptor are not known. Pheochromocytoma PC12 cells express I1-imidazoline binding sites in plasma membrane and lack alpha2-adrenergic receptors, which recognize many I1-imidazoline ligands. In this cellular model, diacylglycerol (DAG), a second messenger, is generated in response to the putative I1-imidazoline agonist moxonidine. Using radioflux with [3H]myristate and direct measurements of DAG mass, we showed a rapid and transient peak of DAG in undifferentiated PC12 cells within the first 1 min of agonist exposure. In PC12 cells treated with nerve growth factor to initiate differentiation, DAG accumulation at 15 sec was facilitated, and the increase in DAG mass persisted throughout 10 min of agonist treatment. Efaroxan, a putative I1-antagonist, attenuated the effect of moxonidine on DAG accumulation in nerve growth factor-treated cells, as did D609, an inhibitor of phosphatidylcholine-selective phospholipase C. Phospholipase D did not seem to be involved in generation of DAG in response to I1-receptor activation, nor was there accumulation of phosphatidic acid. These findings suggest coupling of I1-imidazoline receptors to a phospholipase C to generate DAG as a second messenger, a process regulated by neuronal differentiation and possibly participating in the physiological responses to I1-imidazoline receptor activation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8609895

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  8 in total

1.  Lipid-lowering actions of imidazoline antihypertensive agents in metabolic syndrome X.

Authors:  Rodney A Velliquette; Rachel Kossover; Stephen F Previs; Paul Ernsberger
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-01-17       Impact factor: 3.000

Review 2.  The I1-imidazoline receptor: from binding site to therapeutic target in cardiovascular disease.

Authors:  P Ernsberger; J E Friedman; R J Koletsky
Journal:  J Hypertens Suppl       Date:  1997-01

3.  Rilmenidine improves hepatic steatosis through p38-dependent pathway to higher the expression of farnesoid X receptor.

Authors:  Po-Sheng Yang; Hung-Tsung Wu; Hsien-Hui Chung; Chun-Ta Chen; Chin-Wen Chi; Ching-Hua Yeh; Juei-Tang Cheng
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-09-25       Impact factor: 3.000

4.  LNP 906, the first high-affinity photoaffinity ligand selective for I1 imidazoline receptors.

Authors:  Dragan Urosevic; Urosevic Dragan; Stephan Schann; Schann Stephan; Jean-Daniel Ehrhardt; Ehrhardt Jean-Daniel; Pascal Bousquet; Bousquet Pascal; Hugues Greney; Greney Hugues
Journal:  Br J Pharmacol       Date:  2004-06       Impact factor: 8.739

5.  Inhibition of nischarin expression attenuates rilmenidine-evoked hypotension and phosphorylated extracellular signal-regulated kinase 1/2 production in the rostral ventrolateral medulla of rats.

Authors:  Jian Zhang; Abdel A Abdel-Rahman
Journal:  J Pharmacol Exp Ther       Date:  2007-10-16       Impact factor: 4.030

Review 6.  Agmatine and imidazoline receptors: their role in opioid analgesia, tolerance and dependence.

Authors:  Ning Wu; Rui-Bin Su; Jin Li
Journal:  Cell Mol Neurobiol       Date:  2007-07-25       Impact factor: 5.046

7.  I1 imidazoline receptor: novel potential cytoprotective target of TVP1022, the S-enantiomer of rasagiline.

Authors:  Yaron D Barac; Orit Bar-Am; Esti Liani; Tamar Amit; Luba Frolov; Elena Ovcharenko; Itzchak Angel; Moussa B H Youdim; Ofer Binah
Journal:  PLoS One       Date:  2012-11-15       Impact factor: 3.240

Review 8.  Brain stem adenosine receptors modulate centrally mediated hypotensive responses in conscious rats: A review.

Authors:  Noha N Nassar; Abdel A Abdel-Rahman
Journal:  J Adv Res       Date:  2014-12-18       Impact factor: 10.479

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.